和元生物
(688238)
| 流通市值：21.70亿 | | | 总市值：30.18亿 |
| 流通股本：4.67亿 | | | 总股本：6.49亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 344,381,917.11 | 486,008,211.47 | 566,941,878.98 | 657,048,399.97 |
| 应收票据及应收账款 | 69,088,038.07 | 68,000,210.89 | 57,505,609.35 | 69,200,040.79 |
| 应收账款 | 69,088,038.07 | 68,000,210.89 | 57,505,609.35 | 69,200,040.79 |
| 预付款项 | 9,620,975.51 | 7,840,289.13 | 7,480,025.31 | 6,470,141.32 |
| 其他应收款合计 | 2,052,365.77 | 1,986,375.12 | 2,172,575.02 | 1,890,228.57 |
| 存货 | 80,247,136.18 | 82,889,439.9 | 82,064,223.89 | 80,848,508.12 |
| 合同资产 | 33,454,877.8 | 27,287,035.73 | 32,261,170.28 | 19,765,208.55 |
| 其他流动资产 | 118,728,993.42 | 103,722,690.89 | 101,584,110.4 | 92,227,313.14 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 737,574,303.86 | 777,734,253.13 | 860,070,593.23 | 927,449,840.46 |
| 非流动资产: | | | | |
| 长期股权投资 | 66,641,541.73 | 67,309,632.71 | 66,376,783.46 | 66,922,038.29 |
| 其他权益工具投资 | 52,022,085.28 | 50,453,227.48 | 52,504,412.12 | 40,571,478.85 |
| 固定资产 | 1,332,193,718.51 | 1,355,164,998.61 | 1,165,490,422.98 | 1,045,862,859.74 |
| 在建工程 | 61,947,374.4 | 68,527,645.41 | 243,577,311.12 | 346,324,375.19 |
| 使用权资产 | 1,004,547.6 | 28,942,027.47 | 31,023,083.52 | 32,829,714.06 |
| 无形资产 | 55,323,721.3 | 54,647,250.77 | 55,010,967.69 | 55,491,731.97 |
| 长期待摊费用 | 8,685,043.2 | 36,479,329 | 38,743,541.25 | 40,223,556.19 |
| 递延所得税资产 | 37,908,516.35 | 43,256,989.39 | 56,167,074.55 | 47,816,630.75 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,615,726,548.37 | 1,704,781,100.84 | 1,708,893,596.69 | 1,676,042,385.04 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,353,300,852.23 | 2,482,515,353.97 | 2,568,964,189.92 | 2,603,492,225.5 |
| 流动负债: | | | | |
| 短期借款 | 70,042,000.01 | 60,040,000 | 60,016,666.66 | - |
| 应付票据及应付账款 | 153,989,198.17 | 186,625,153.11 | 176,469,880.93 | 228,501,697.51 |
| 其中：应付票据 | - | 195,618 | - | - |
| 应付账款 | 153,989,198.17 | 186,429,535.11 | 176,469,880.93 | 228,501,697.51 |
| 合同负债 | 25,684,363.49 | 29,080,945.31 | 23,346,514.04 | 35,037,513.31 |
| 应付职工薪酬 | 11,845,327.46 | 12,444,762.4 | 14,060,807.6 | 17,643,402.34 |
| 应交税费 | 2,528,819.75 | 2,166,432.45 | 5,538,528.45 | 6,417,428.56 |
| 其他应付款合计 | 6,571,648.27 | 6,280,569.66 | 24,969,243.5 | 6,082,576.86 |
| 一年内到期的非流动负债 | 17,689,394.59 | 25,519,906.58 | 20,292,441.38 | 18,341,866.76 |
| 其他流动负债 | 1,594,318.94 | 1,826,685.83 | 1,461,318.17 | 2,146,478.81 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 289,945,070.68 | 323,984,455.34 | 326,155,400.73 | 314,170,964.15 |
| 非流动负债: | | | | |
| 长期借款 | 128,021,500 | 135,505,000 | 142,988,500 | 144,222,000 |
| 租赁负债 | 952,776.43 | 25,819,427.07 | 26,790,878.21 | 28,565,868.04 |
| 预计负债 | 950,890.03 | 2,435,131.45 | 2,977,761.45 | 2,670,391.45 |
| 递延收益 | 65,085,784.08 | 47,049,195.75 | 48,705,245.74 | 50,451,947.61 |
| 递延所得税负债 | 251,136.91 | 4,447,786.17 | 4,775,121.84 | 5,042,993.73 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 195,262,087.45 | 215,256,540.44 | 226,237,507.24 | 230,953,200.83 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 485,207,158.13 | 539,240,995.78 | 552,392,907.97 | 545,124,164.98 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 647,433,100 | 647,433,100 | 647,433,100 | 647,433,100 |
| 资本公积 | 1,446,298,584.14 | 1,446,298,584.14 | 1,446,277,690.32 | 1,445,337,486.87 |
| 其他综合收益 | -613,128.05 | -2,079,415.32 | -65,287.65 | 372,924.09 |
| 盈余公积 | 9,313,913.89 | 9,313,913.89 | 9,313,913.89 | 9,313,913.89 |
| 未分配利润 | -233,980,756.62 | -157,559,377.05 | -86,384,292.08 | -44,213,999.76 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,868,451,713.36 | 1,943,406,805.66 | 2,016,575,124.48 | 2,058,243,425.09 |
| 少数股东权益 | -358,019.26 | -132,447.47 | -3,842.53 | 124,635.43 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,868,093,694.1 | 1,943,274,358.19 | 2,016,571,281.95 | 2,058,368,060.52 |
| 负债和股东权益合计 | 2,353,300,852.23 | 2,482,515,353.97 | 2,568,964,189.92 | 2,603,492,225.5 |
| 公告日期 | 2024-10-24 | 2024-08-29 | 2024-04-29 | 2024-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |